Literature DB >> 9626863

Renal MR angiography: a comprehensive approach.

M R Prince1.   

Abstract

Renal artery MR angiography has now emerged as a safe, accurate approach to renal arteriography. A comprehensive examination, including both three-dimensional (3D) dynamic gadolinium-enhanced and 3D phase contrast MRA techniques, allows evaluation of both the aorta-renal and splanchnic arterial anatomy as well as the hemodynamic significance of any stenoses identified. The 3D gadolinium-enhanced MRA technique produces a contrast arteriogram but without risks of iodinated contrast or ionizing radiation. The 3D phase contrast technique is a flow-based technique, which may show dephasing in the presence of hemodynamically significant stenoses. A comprehensive examination should also include T1- and T2-weighted imaging for the assessment of potential neoplastic masses and the ubiquitous renal cysts. Through trial and error over the course of over a thousand examinations, this comprehensive approach to the MR evaluation of renal vascular pathology has emerged.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626863     DOI: 10.1002/jmri.1880080302

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  3 in total

1.  Vascular lesions of the renal sinus.

Authors:  Gabriela Gayer; Rivka Zissin; Uri Rimon; Larisa Guranda; Sara Apter; Marjorie Hertz
Journal:  Emerg Radiol       Date:  2003-09-06

2.  Assessment of the kidneys: magnetic resonance angiography, perfusion and diffusion.

Authors:  Ulrike I Attenberger; John N Morelli; Stefan O Schoenberg; Henrik J Michaely
Journal:  J Cardiovasc Magn Reson       Date:  2011-11-15       Impact factor: 5.364

Review 3.  Atherosclerotic renal artery stenosis and renovascular hypertension: clinical diagnosis and indications for revascularization.

Authors:  Edmund Kenneth Kerut; Stephen A Geraci; Chester Falterman; David Hunter; Curtis Hanawalt; Thomas D Giles
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-07       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.